[TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]
- PMID: 7723714
[TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]
Abstract
Background: Deficient retinal capillary perfusion results in angioneogenesis of the eye. Its extension depends on the degree of ischemia. Mild stages are restricted to the retina, while marked ischemia results in neovascularization of the iris (rubeosis iridis). The neovascularization may be induced by the release of growth factors into the vitreous. Tumor necrosis factor alpha seems to be an important angiogenetic growth factor.
Patients and methods: The patients were divided up into three groups with different retinal stages of ischemia, as judged by the extension of new vessel formation of the eye: a control group without angioneogenesis, a diabetes group with less severe to moderate angioneogenesis of patients with proliferative diabetic retinopathy and a rubeosis group with massive angiogenesis (rubeosis iridis) resulting from different causes. TNF-alpha was determined by immunological methods.
Results: The TNF-alpha level of vitreous in rubeosis (25.8 pg/ml; n = 6) was 2-fold elevated compared to controls (13.1 pg/ml; n = 10; p < 0.05) and 1.4-fold elevated compared to the diabetes group (18.2 pg/ml; n = 17). The values ranged from unmeasurable values to 41.25 pg/ml. Within the rubeosis group similar changes were observed independently of the causes of ischemia. There was no correlation between TNF-alpha-levels in the diabetes group and serum creatinine.
Conclusions: 1. TNF-alpha is upregulated in ischemia. 2. TNF-alpha seems to be a mediator of angiogenesis in the eye. 3. Changes in diabetes may be secondary to local ischemia rather than being specific for diabetic retinopathy.
Similar articles
-
Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.J Clin Invest. 1993 Dec;92(6):2620-5. doi: 10.1172/JCI116877. J Clin Invest. 1993. PMID: 7504689 Free PMC article.
-
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.N Engl J Med. 2005 Aug 25;353(8):782-92. doi: 10.1056/NEJMoa041773. N Engl J Med. 2005. PMID: 16120858
-
Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease.Exp Clin Endocrinol Diabetes. 1999;107(1):21-8. doi: 10.1055/s-0029-1212068. Exp Clin Endocrinol Diabetes. 1999. PMID: 10077351
-
Management of proliferative diabetic retinopathy.Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56. Compr Ophthalmol Update. 2007. PMID: 18201511 Review.
-
The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model.Ophthalmic Surg. 1980 Apr;11(4):235-45. Ophthalmic Surg. 1980. PMID: 6155650 Review.
Cited by
-
Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation.Graefes Arch Clin Exp Ophthalmol. 2004 May;242(5):409-13. doi: 10.1007/s00417-004-0874-2. Epub 2004 Mar 17. Graefes Arch Clin Exp Ophthalmol. 2004. PMID: 15029502
-
Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells.Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4342-7. doi: 10.1167/iovs.05-0601. Invest Ophthalmol Vis Sci. 2005. PMID: 16249517 Free PMC article.
-
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2.Br J Ophthalmol. 2007 Apr;91(4):538-45. doi: 10.1136/bjo.2006.101543. Epub 2006 Aug 30. Br J Ophthalmol. 2007. PMID: 16943230 Free PMC article.
-
Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy.Clin Exp Immunol. 1999 Mar;115(3):409-14. doi: 10.1046/j.1365-2249.1999.00839.x. Clin Exp Immunol. 1999. PMID: 10193411 Free PMC article.
-
TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis.Invest Ophthalmol Vis Sci. 2011 Mar 10;52(3):1336-44. doi: 10.1167/iovs.10-5768. Print 2011 Mar. Invest Ophthalmol Vis Sci. 2011. PMID: 21212173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical